Calpain inhibitor A-558693 in experimental focal cerebral ischemia in rats

Neurological Research

Volumn 27, Issue 5, 2005, Pages 466-470

  Liebetrau, Martin ^a   Martens, Helge ^a   Thomassen, Nora ^a   Burggraf, Dorothe ^a   Gabrijelcic Geiger, Dusica ^a,b   Lubisch, Wolfgang ^a,b   Möller, Achim ^a   Hamann, Gerhard F ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Calpain inhibitor; Immunohistochemistry; MAP 2; Middle cerebral artery occlusion

Indexed keywords

A 558693; CALPAIN; CALPASTATIN; MICROTUBULE ASSOCIATED PROTEIN 2; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; HEMISPHERE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; REPERFUSION; VOLUMETRY; WESTERN BLOTTING;

AMIDES; ANIMALS; BLOTTING, WESTERN; BRAIN INFARCTION; BRAIN ISCHEMIA; CALPAIN; CELL COUNT; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; RATS; RATS, WISTAR; REPERFUSION INJURY;

EID: 22844449213     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164105X15712     Document Type: Article

References (25)

1. Croall DE, DeMartino GN. Calcium-activated neutral protease (calpain) system: Structure, function, and regulation. Physiol Rev 1991; 71: 813-847
2. Takagaki Y, Itoh Y, Aoki Y, et al. Inhibition of ischemia-induced fodrin breakdown by a novel phenylpyrimidine derivative NS-7: An implication for its neuroprotective action in rats with middle cerebral artery occlusion. J Neurochem 1997; 68: 2507-2513
3. Saatman KE, Bozyczko CD, Marcy V, et al. Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. J Neuropathol Exp Neurol 1996; 55: 850-860
4. Siman R, Card JP, Davis LG. Proteolytic processing of beta-amyloid precursor by calpain I. J Neurosci 1990; 10: 2400-2411
5. Zivin JA, Choi DW. Stroke therapy. Sci Am 1991; 265: 56-63
6. Bartus RT, Dean RL, Cavanaugh K, et al. Time-related neuronal changes following middle cerebral artery occlusion: Implications for therapeutic intervention and the role of calpain. J Cereb Blood Flow Metab 1995; 15: 969-979
7. Liebetrau M, Staufer B, Auerswald EA, et al. Increased intracellular calpain detection in experimental focal cerebral ischemia. Neuroreport 1999; 10: 529-534
8. Kampfl A, Posmantur RM, Zhao X, et al. Mechanisms of calpain proteolysis following traumatic brain injury: Implications for pathology and therapy: A review and update. J Neurotrauma 1997; 14: 121-134
9. Saido TC, Sorimachi H, Suzuki K. Calpain: New perspectives in molecular diversity and physiological-pathological involvement. FASEB J 1994; 8: 814-822
10. Dawson DA, Hallenbeck JM. Acute focal ischemia-induced alterations in MAP2 immunostaining: Description of temporal changes and utilization as a marker for volumetric assessment of acute brain injury. J Cereb Blood Flow Metab 1996; 16: 170-174
11. Posmantur R, Kampfl A, Siman R, et al. A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat. Neuroscience 1997; 77: 875-888
12. Lofvenberg L, Backman L. Calpain-induced proteolysis of beta-spectrins. FEBS Lett 1999; 443: 89-92
13. Liebetrau M, Burggraf D, Martens HK, et al. Delayed moderate hypothermia reduces calpain activity and breakdown of its substrate in experimental focal cerebral ischemia in rats. Neurosci Lett 2004; 357: 17-20
14. Hong SC, Goto Y, LanzinoG, et al. Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia. Stroke 1994; 25: 663-669
15. Bartus RT, Baker KL, Heiser AD, et al. Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J Cereb Blood Flow Metab 1994; 14: 537-544
16. Bartus RT, Hayward NJ, Elliott PJ, et al. Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration. Stroke 1994; 25: 2265-2270
17. Markgraf CG, Velayo NL, Johnson MP, et al. Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke 1998; 29: 152-158
18. Lubisch W, Beckenbach E, Bopp S, et al. Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: Discovery of potent water-soluble calpain inhibitors with oral bioavailability. J Med Chem 2003; 46: 2404-2412
19. Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91
20. Moller JC, Klein MA, Haas S, et al. Regulation of thrombospondin in the regenerating mouse facial motor nucleus. Glia 1996; 17: 121-132
21. Hamann GF, Liebetrau M, Martens H, et al. Microvascular basal lamina injury after experimental focal cerebral ischemia and reperfusion in the rat. J Cereb Blood Flow Metab 2002; 22: 526-533
22. Kloss CU, Thomassen N, Fesl G, et al. Tissue-saving infarct volumetry using histochemistry validated by MRI in rat focal ischemia. Neurol Res 2002; 24: 713-718
23. Liebetrau M, Gabriejcic-Geiger D, Meyer P, et al. Increased calpain expression following experimental cerebral venous thrombosis in rats. Thromb Res 2003; 112: 239-243
24. Pettigrew LC, Holtz ML, Craddock SD, et al. Microtubular proteolysis in focal cerebral ischemia. J Cereb Blood Flow Metab 1996; 16: 1189-1202
25. Li PA, Hewlett W, He QP, et al. Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. Neurosci Lett 1998; 247: 17-20